Selective gene delivery for cancer therapy using cationic liposomes: in vivo proof of applicability.
Targeted gene therapy is essential if cancer treatment is to become a reality with this form of therapy. In the past few years, cationic liposomes, discovered 2 decades ago, and at present, the most commonly used class of transfection reagents, have been tested in various clinical trials for diseases not restricted to cancer. They have been shown to be selective for tumour vascular endothelial cells raising hopes for antiangiogenic and antivascular therapies. They are also capable of being selectively delivered to the lungs and liver when administered intravenously. These vesicles are also being targeted to the tumour in various parts of the body by using advanced liposomal systems such as antibody-antigen and ligand-receptor combinations. This review looks at the state of play in this rapidly growing field.
Dass
Crispin R
CR
Department of Orthopaedics, University of Melbourne, St. Vincent's Hospital Melbourne, P.O. Box 2900, Fitzroy 3065, Australia. crispin.dass@svhm.org.au
Choong
Peter F M
PF
D000818:Animals; D002412:Cations / Q000008:administration & dosage; D018390:Gene Targeting / Q000379:methods*; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D008081:Liposomes; D009369:Neoplasms / Q000188:drug therapy / Q000235:genetics*
D002412:Cations; D008081:Liposomes